Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

This potential new belongs to a class of receptors called the nicotinic acetylcholine receptors (nAChRs). One subtype of nAChRs, called alpha4beta2 is a well-known target for nicotine's and the therapeutic effect of the drug varenicline. SRI researchers are now studying another, lesser-known subtype, called alpha3beta4 nAChR, which has recently shown to play a role in the addictive properties of cocaine, morphine, and nicotine.

Using AT-1001, a highly selective alpha3beta4 compound developed by Astraea Therapeutics, SRI researchers found that addiction processes could be disrupted. In preliminary studies, AT-1001 also reduced nicotine withdrawal symptoms such as anxiety.

Because act on the brain's "reward circuit," many people compulsively take them despite their harmful consequences. Feelings of pleasure are caused by the release of , or neurotransmitters, and their increased activity in the circuit. The key neurotransmitter in the reward circuit is dopamine, which produces changes in addictive behavior. Researchers speculate that disruption of the alpha3beta4 nAChR system using highly selective drugs such as AT-1001 may interrupt this reward circuitry.

"Currently, there are no therapeutics approved to treat addiction to stimulants such as cocaine, so it is intriguing to find a promising drug receptor target and to see that AT-1001 can indeed affect phenomena that are thought to be deeply tied to the addictive nature of cocaine and other drugs of abuse," said Taline Khroyan, Ph.D., Senior Behavioral Pharmacologist in SRI's Center for Health Sciences.

Findings from these collaborative studies were recently presented at the Society for Neuroscience Annual Meeting in a study titled "AT-1001, a Highly Selective alpha3beta4 nicotinic Receptor Antagonist is Effective in Blocking Place Preference, Behavioral Sensitization, and Withdrawal Effects of Various Drugs of Abuse." The presentation was highlighted by the Society for describing the innovative approach taken by the research team.

Related Stories

Recommended for you

Smokers who use e-cigarettes less likely to quit

date Apr 16, 2015

The rapid increase in use of e-cigarettes has led to heated debates between opponents who question the safety of these devices and proponents who claim the battery-operated products are a useful cessation tool. A study, published ...

Evidence that synthetic drugs can cause cancer

date Apr 16, 2015

Almost weekly, a new synthetic psychoactive drug comes onto the market somewhere in Europe that can be ordered legally and easily, for example as an incense blend, via the Internet. Synthetic cannabinoids ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.